A Comparative Study of Attenuation of Hypertensive Response with Esmolol and Labetalol in Low doses in Orotracheal Intubation

S. Ambasta, S. Mahapatra
{"title":"A Comparative Study of Attenuation of Hypertensive Response with Esmolol and Labetalol in Low doses in Orotracheal Intubation","authors":"S. Ambasta, S. Mahapatra","doi":"10.9734/bpi/nfmmr/v16/3775f","DOIUrl":null,"url":null,"abstract":"Introduction: Esmolol and Labetalol, at low doses, were evaluated for attenuation of sympathomimetic reaction to laryngoscopy and intubation in this prospective, randomised, double-blind, comparative clinical study. \nMaterials and Methods: This study involved 50 ASA 1 patients of either sex who were undergoing elective surgery under general anaesthesia. Prior to induction, patients were randomly assigned to one of two groups: group E got intravenous Esmolol (0.5 mg/kg) or group L received intravenous Labetalol (0.25 mg/kg), and hemodynamic parameters were monitored as per the procedure to determine stress response to laryngoscopy and intubation. \nResults: The demographic profiles of both research groups were similar. For statistical calculations, Instat version 3.10 was utilised. The data from the study was evaluated using statistical approaches such as mean and standard deviation. During laryngoscopy and intubation, esmolol (0.5 mg/kg) and Labetalol (0.25 mg/kg) significantly reduced the increase in heart rate, systolic blood pressure, and RPP. However, the difference was not statistically significant among the values for DBP and MAP. \nConclusion: In lower doses, intravenous Labetalol (0.25 mg/kg) is a better agent than intravenous Esmolol (0.5 mg/kg) in attenuating the sympathomimetic reaction to laryngoscopy and intubation, according to our clinical trial. The typical dose of esmolol used to obtund intubation response is 2-4 mg/kg, whereas labetalol has been tested in all doses ranging from 0.25, 0.5, 0.75, and 1 mg/kg [1].","PeriodicalId":436259,"journal":{"name":"New Frontiers in Medicine and Medical Research Vol. 16","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Frontiers in Medicine and Medical Research Vol. 16","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/bpi/nfmmr/v16/3775f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Esmolol and Labetalol, at low doses, were evaluated for attenuation of sympathomimetic reaction to laryngoscopy and intubation in this prospective, randomised, double-blind, comparative clinical study. Materials and Methods: This study involved 50 ASA 1 patients of either sex who were undergoing elective surgery under general anaesthesia. Prior to induction, patients were randomly assigned to one of two groups: group E got intravenous Esmolol (0.5 mg/kg) or group L received intravenous Labetalol (0.25 mg/kg), and hemodynamic parameters were monitored as per the procedure to determine stress response to laryngoscopy and intubation. Results: The demographic profiles of both research groups were similar. For statistical calculations, Instat version 3.10 was utilised. The data from the study was evaluated using statistical approaches such as mean and standard deviation. During laryngoscopy and intubation, esmolol (0.5 mg/kg) and Labetalol (0.25 mg/kg) significantly reduced the increase in heart rate, systolic blood pressure, and RPP. However, the difference was not statistically significant among the values for DBP and MAP. Conclusion: In lower doses, intravenous Labetalol (0.25 mg/kg) is a better agent than intravenous Esmolol (0.5 mg/kg) in attenuating the sympathomimetic reaction to laryngoscopy and intubation, according to our clinical trial. The typical dose of esmolol used to obtund intubation response is 2-4 mg/kg, whereas labetalol has been tested in all doses ranging from 0.25, 0.5, 0.75, and 1 mg/kg [1].
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
低剂量艾司洛尔与拉贝他洛尔对经气管插管降压作用的比较研究
在这项前瞻性、随机、双盲、比较临床研究中,评估了低剂量的艾司洛尔和拉贝他洛尔对喉镜检查和插管的拟交感神经反应的衰减。材料和方法:本研究包括50例ASA 1级患者,男女不限,在全身麻醉下进行择期手术。诱导前,将患者随机分为两组:E组静脉注射艾司洛尔(0.5 mg/kg), L组静脉注射拉贝他洛尔(0.25 mg/kg),并按程序监测血流动力学参数,以确定对喉镜检查和插管的应激反应。结果:两个研究组的人口统计资料相似。对于统计计算,使用了Instat 3.10版本。该研究的数据使用均值和标准差等统计方法进行评估。在喉镜检查和插管时,艾司洛尔(0.5 mg/kg)和拉贝他洛尔(0.25 mg/kg)显著降低了心率、收缩压和RPP的升高。然而,DBP和MAP值之间的差异无统计学意义。结论:根据我们的临床试验,在低剂量情况下,静脉注射拉贝他洛尔(0.25 mg/kg)比静脉注射艾司洛尔(0.5 mg/kg)更能减轻喉镜和插管的拟交感神经反应。用于抑制插管反应的艾司洛尔的典型剂量为2-4毫克/千克,而拉贝他洛尔已在0.25、0.5、0.75和1毫克/千克[1]的所有剂量范围内进行了测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A Retrospective Clinicopathological Study of Cervical Cancer A Review and Update on Clinical Management on Burning Mouth Syndrome Investigating the Effects of Standardised Treatment Protocols for Opportunistic Infection in Children Living with HIV/AIDS on Their Clinical Profile Study on Nasopalatine Duct Cyst: A Common Lesion with Uncommon Presentation in a Young Girl Alveolar Bone and Epithelial Attachment Status following Two Different Closed-eruption Surgical Techniques for Impacted Maxillary Central Incisors: A Recent Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1